FOOD INTERACTION AND STEADY-STATE PHARMACOKINETICS OF ITRACONAZOLE CAPSULES IN HEALTHY MALE-VOLUNTEERS

被引:192
作者
BARONE, JA
KOH, JG
BIERMAN, RH
COLAIZZI, JL
SWANSON, KA
GAFFAR, MC
MOSKOVITZ, BL
MECHLINSKI, W
VANDEVELDE, V
机构
[1] JANSSEN RES FDN,BEERSE,BELGIUM
[2] RUTGERS STATE UNIV,HURTADO STUDENT HLTH CTR,NEW BRUNSWICK,NJ 08903
[3] JANSSEN RES FDN,TITUSVILLE,NJ 08560
关键词
D O I
10.1128/AAC.37.4.778
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The influence of food on itraconazole pharmacokinetics was evaluated for 27 healthy male volunteers in a single-dose (200 mg) crossover study with capsules containing itraconazole-coated sugar spheres. This study was followed by a study of the steady-state pharmacokinetics for the same subjects with 15 days of administration of itraconazole at 200 mg every 12 h. Concentrations of itraconazole and hydroxyitraconazole, the active main metabolite, were measured in plasma by high-performance liquid chromatography. The results of the food interaction segment showed that a meal significantly enhances the amount of itraconazole absorbed. The mean maximum concentration in plasma of unmetabolized itraconazole after fasting (140 ng/ml) was about 59% that after the standard meal (239 ng/ml). The rate of elimination was not affected (terminal half-life, approximately 21 h). The mean maximum concentration in plasma of hydroxyitraconazole after fasting was about 72% the postmeal concentration (287 and 397 ng/ml, respectively). The terminal half-life of hydroxyitraconazole was approximately 12 h. Steady-state concentrations of itraconazole and hydroxyitraconazole were reached after 14 or 15 days of daily dosing. The average steady-state concentrations were approximately 1,900 ng/ml for itraconazole and 3,200 ng/ml for hydroxyitraconazole. The shape of the elimination curve for itraconazole after the last dose was indicative of saturable elimination. This conclusion was confirmed by the sevenfold increase in the area under the curve from 0 to 12 h at steady state compared with the area under the curve from 0 h to infinity after a single dose. It was furthermore confirmed by the larger-than-expected number of half-lives required to achieve steady-state plasma drug levels.
引用
收藏
页码:778 / 784
页数:7
相关论文
共 12 条
  • [1] BAILEY EM, 1990, PHARMACOTHERAPY, V10, P146
  • [2] ITRACONAZOLE IN ANTIFUNGAL THERAPY
    CLEARY, JD
    TAYLOR, JW
    CHAPMAN, SW
    [J]. ANNALS OF PHARMACOTHERAPY, 1992, 26 (04) : 502 - 509
  • [3] Cutsem J. van, 1987, Recent trends in the discovery, development and evaluation of antifungal agents., P177
  • [4] DUPONT B, 1987, REV INFECT DIS, V9, pS71
  • [5] NON-LINEAR PHARMACOKINETICS OF THE NEW POSITIVE INOTROPIC AGENT SULMAZOLE IN THE DOG
    GARRETT, ER
    ROTH, W
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (02) : 105 - 116
  • [6] 2-PERIOD CHANGE-OVER DESIGN AND ITS USE IN CLINICAL TRIALS
    GRIZZLE, JE
    [J]. BIOMETRICS, 1965, 21 (02) : 467 - &
  • [7] PHARMACOKINETICS OF ITRACONAZOLE FOLLOWING ORAL-ADMINISTRATION TO NORMAL VOLUNTEERS
    HARDIN, TC
    GRAYBILL, JR
    FETCHICK, R
    WOESTENBORGHS, R
    RINALDI, MG
    KUHN, JG
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (09) : 1310 - 1313
  • [8] THE CLINICAL PHARMACOKINETICS OF ITRACONAZOLE - AN OVERVIEW
    HEYKANTS, J
    VANPEER, A
    VANDEVELDE, V
    VANROOY, P
    MEULDERMANS, W
    LAVRIJSEN, K
    WOESTENBORGHS, R
    VANCUTSEM, J
    CAUWENBERGH, G
    [J]. MYCOSES, 1989, 32 : 67 - 87
  • [9] SHIURMAN D, 1987, J PHARMACOKINET BIOP, V15, P657
  • [10] THE EFFECTS OF FOOD AND DOSE ON THE ORAL SYSTEMIC AVAILABILITY OF ITRACONAZOLE IN HEALTHY-SUBJECTS
    VANPEER, A
    WOESTENBORGHS, R
    HEYKANTS, J
    GASPARINI, R
    GAUWENBERGH, G
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (04) : 423 - 426